Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
BRAF Mutation-Related Tumors: early-phase trial registry
2 of 3 indexed BRAF Mutation-Related Tumors trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
BRAF Mutation-Related Tumors: 3 US clinical trials tracked, 2 recruiting.
BRAF Mutation-Related Tumors is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Institut de Recherches Internationales Servier, running 1 of these trials.
Enrollment posture brief
Registry condition braf-mutation-related-tumors
OPEN 2 | RECR 67% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
BRAF Mutation-Related Tumors lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for BRAF Mutation-Related Tumors on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
BRAF Mutation-Related Tumors is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Institut de Recherches Internationales Servier
NCT05786924
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
UNC Lineberger Comprehensive Cancer Center
NCT06902376
Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
Memorial Sloan Kettering Cancer Center
NCT04238624
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on BRAF Mutation-Related Tumors records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on BRAF Mutation-Related Tumors trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this BRAF Mutation-Related Tumors page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 BRAF Mutation-Related Tumors trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Institut de Recherches Internationales Servier sponsors the most BRAF Mutation-Related Tumors trials on record, review their full trial history before evaluating a specific study. See Institut de Recherches Internationales Servier's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This BRAF Mutation-Related Tumors condition card totals 3 registered trials; most-linked intervention FOLFOX6/FOLFOX7; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.